CelLBxHealth PLC has completed a strategic reset focusing on cost reduction and shifting to partner-led commercialization of its Parsortix platform. The company reduced operating costs by 60% and consolidated operations to extend its cash runway into Q2 2027. Partnerships with firms like Myriad Genetics and AstraZeneca validate its new approach, with revenue forecasted to grow 55% to £2.1m in 2026 and reach £8.3m by 2028. The company aims to turn cash-flow positive by 2028, with key value drivers being pipeline conversion and partnership monetization over the next 12 to 18 months.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
